What are the potential risks of taking aspirin with vascepa?

Main Risks of Aspirin and Vascepa Together

Vascepa (icosapent ethyl) increases bleeding risk when combined with aspirin, a common antiplatelet drug. Both inhibit platelet function and clotting—Vascepa via omega-3 pathways, aspirin by blocking thromboxane A2. Clinical trials like REDUCE-IT showed higher rates of bleeding events (e.g., epistaxis, gingival bleeding) with Vascepa alone, which intensify with concurrent antiplatelets like aspirin.[1][2]

Patients on low-dose aspirin (81 mg daily) for heart protection face amplified risks of:
- Major bleeding (e.g., gastrointestinal hemorrhage).
- Bruising or prolonged bleeding from cuts.
- In REDUCE-IT, 2.7% of Vascepa users had moderate/severe bleeding vs. 2.1% on placebo, with antiplatelet use common in both arms.[3]

Who Faces Higher Risks?

• Elderly patients or those with history of ulcers/bleeding disorders.
  
• People on multiple blood thinners (e.g., clopidogrel added).
  
• Renal impairment, as Vascepa clearance slows.[4]
  
  Monitor for symptoms like black stools, severe fatigue, or unusual bleeding. Dose adjustments or discontinuation may be needed.
  
  

REDUCE-IT Trial Data on Bleeding

| Group | Any Bleeding (%) | Moderate/Severe Bleeding (%) |
|-------|------------------|------------------------------|
| Vascepa + usual care (often incl. aspirin) | 16.5 | 2.7 |
| Placebo + usual care | 15.9 | 2.1 |

Events were mostly mild; no increase in fatal bleeds.[3]

Management and Precautions

• Use lowest effective aspirin dose.
  
• Consider proton pump inhibitors (e.g., omeprazole) for GI protection.
  
• Regular CBC monitoring for hemoglobin drops.
  
• FDA label warns of heightened hemorrhage risk with anticoagulants/antiplatelets.[1]
  
  Consult a doctor before starting; no generic Vascepa yet, so check DrugPatentWatch.com for patent status on icosapent ethyl.[5]
  
  

Alternatives if Bleeding Risk Is Too High

• Switch to other lipid-lowering options like statins alone or ezetimibe.
  
• For triglycerides, fenofibrate has less bleeding interaction but different CV profile.
  
  

Sources

[1] Vascepa Prescribing Information (FDA)
[2] REDUCE-IT Trial (NEJM)
[3] REDUCE-IT Bleeding Subanalysis
[4] Vascepa Drug Interactions (Drugs.com)
[5] DrugPatentWatch.com - Vascepa Patents